Abstract library

19 results for "Mełen-Mucha".
#2043 Combination of Surgery and Ethanol Ablation in a MEN-2A Patient
Introduction: MEN-2A is an autosomal dominant syndrome characterized by pheochromocytoma, medullary thyroid carcinoma and hyperparathyroidism.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Prof. Huang-Ying Tan
Authors: Fang Z L, Tan H Y, Wang Y, Cai X P, ...
#1200 Clinical Outcome of Everolimus Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Data from the German NET-Register
Introduction: Everolimus (EVE) has importantly impacted the treatment (Tx) of mostly pancreatic NEN.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Sebastian Maasberg
Authors: Pape U F, Bacher M, Fottner C, Lahner H, ...
Keywords: everolimus, outcome
#292 Early Detection of Gastric GIST Tumor in a Patient with Rectal Neuroendocrine Cancer – A Case Report
Introduction: A case of a 60-year-old man with rectal neuroendocrine cancer, in whom gastric GIST tumor was detected in March 2009, is presented.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: professor Gabriela Melen-Mucha
Authors: Mucha S, Komorowski J, ...
#441 Tie-2 and Angiopoietin-2 Plasma Levels as New Diagnostic Markers for Patients with Neuroendocrine Tumors. Data from One Clinical Center
Introduction: Data concerning circulating levels of the angiogenic factors in patients with neuroendocrine tumors (NET) still remain insufficient.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Gabriela Melen-Mucha
#1205 Temozolomid-Based Therapy in GEP-and Bronchopulmonary NEN from a Multicentric Study from Germany
Introduction: Chemotherapy (CTx) with temozolomid as mono (TEM) or combination therapy with capcitabine (TEM/CAP) is a new cytotoxic regimen with good efficiency in pancreatic and bronchopulmonary NET-G1/G2 and NEC-G3.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Sebastian Maasberg
Authors: Maasberg S, Bacher M, Rinke A, Lahner H, ...
#1443 Second Primary Malignancies Incidence in Patients with Neuroendocrine Tumours – Retrospective Review of 454 Neuroendocrine Tumour Cases
Introduction: Increased incidence of second primary malignancies (SPM) in patients (pts) with neuroendocrine tumors (NET) has been reported.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: MD Karolina Poczkaj
#1648 Treatment Patterns and Survival Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden – A Population-Based Register-Linkage and Medical Chart Review Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a group of neoplasms derived from the endocrine system in the GI tract and pancreas.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Åse Björstad
#1714 CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN)
Introduction: The presence of CTCs confers adverse prognosis in metastatic NET pts with heterogenous treatment history. Post treatment CTC count correlates with disease progression and overall survival.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Kate Higgs
#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study
Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67<10%) NETs, but prospective data on SSAs in advanced lung NETs are lacking.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Diane Reidy-Lagunes
Keywords: Lung NETs, lanreotide
#1798 Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Patients wth Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
Introduction: CLARINET demonstrated the antitumour effect of LAN 120mg/28 days (standard interval) in metastatic gastroenteropancreatic NETs. If disease progresses (PD) on this dose, aggressive treatments (eg targeted therapies) are usually offered.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Marianne Pavel
Authors: Pavel M, Dromain C, Majdi A, Houchard A, ...